Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12908953 | 1.00 | LMNA (0.38) | LMNAGAAKDM4EALDH1A1 | |
| SCHEMBL12038676 | 0.75 | — | — | |
| SCHEMBL979584 | 0.75 | — | — | |
| SCHEMBL12038673 | 0.75 | — | — | |
| SCHEMBL17308871 | 0.73 | LMNA (0.33) | LMNAGAA | |
| SCHEMBL25135257 | 0.71 | CA1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL14844413 | 0.68 | — | — | |
| SCHEMBL363396 | 0.68 | — | — | |
| SCHEMBL5964519 | 0.66 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL20045268 | 0.65 | JUN (0.37) | LMNAGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON | 2009-01-15 | — | — | US | disclosed |
| US-7399782-B2 | Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | CFTR, MUC1, SLC47A1 | LMNA 2233/4885GAA 1563/4885KDM4E 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.